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Maternal smoking during pregnancy is associated with low birth weight. Common variation at rs1051730 is ro-
bustly associated with smoking quantity and was recently shown to influence smoking cessation during preg-
nancy, but its influence on birth weight is not clear. We aimed to investigate the association between this
variant and birth weight of term, singleton offspring in a well-powered meta-analysis. We stratified 26 241
European origin study participants by smoking status (women who smoked during pregnancy versus
women who did not smoke during pregnancy) and, in each stratum, analysed the association between maternal
rs1051730 genotype and offspring birth weight. There was evidence of interaction between genotype and
smoking (P5 0.007). In women who smoked during pregnancy, each additional smoking-related T-allele was
associated with a 20 g [95% confidence interval (95% CI): 4–36 g] lower birth weight (P5 0.014). However, in
women who did not smoke during pregnancy, the effect size estimate was 5 g per T-allele (95% CI: 24 to
14 g; P5 0.268). To conclude, smoking status during pregnancy modifies the association between maternal
rs1051730 genotype and offspring birth weight. This strengthens the evidence that smoking during pregnancy
is causally related to lower offspring birth weight and suggests that population interventions that effectively
reduce smoking in pregnant women would result in a reduced prevalence of low birth weight.
INTRODUCTION
Low birth weight and preterm birth are important risk factors
for perinatal morbidity and mortality (1). Furthermore, lower
birth weight is associated with an increased risk of chronic dis-
eases in adulthood, including cardiovascular disease, high blood
pressure, coronary heart disease, type 2 diabetes and adult mor-
tality (2–5). Maternal smoking during pregnancy is strongly
associated with low birth weight (6,7). Babies whose mothers
smoked during pregnancy are on average 150 to 200 g lighter
at birth than babies with non-smoking mothers (6,8). The
2006 legislation in Scotland, which banned smoking in public
areas, has been associated with a reduced number of preterm
births and small for gestational age babies (9).
Genetic variation at the CHRNA5–CHRNA3–CHRNB4 locus
on chromosome 15q25 is robustly associated with the quantity
of smoking in those who smoke (10–14). Each additional copy
of the risk allele (T) of the single-nucleotide polymorphism
(SNP), rs1051730, is associated with an increase in smoking quan-
tity of approximately one cigarette per day (12). The variant is not
associated with smoking initiation, since it is equally prevalent in
smokers and never-smokers (12). The rs1051730 SNP is also
strongly associated with a reduced ability of women to quit
smoking during pregnancy, and with a higher number of cigarettes
per day in pregnant women who smoke (15,16).
Studies of women from the UK (15) and the Netherlands
(17) have independently investigated the association between
the 15q25 variant and birth weight. Both studies observed
reductions in birth weight with each additional copy of the
maternal risk allele in women who smoked during pregnancy
[228 g (95% confidence interval—95% CI: 259 to 2 g) per
T-allele in n ¼ 1829 UK women; 238 g (95% CI: 289 to
13 g) per T-allele in n ¼ 610 Dutch women]. However, statis-
tical power was limited by the available sample sizes, and
neither association achieved P , 0.05. The association
between the maternal rs1051730 variant and birth weight has
not been investigated in a well-powered sample of mothers
and offspring, and furthermore, any potential associations
with fetal genotype have not been examined.
We therefore performed a meta-analysis of 26 241 women
from 14 studies to assess the evidence for association
between maternal rs1051730 and birth weight, stratified by
maternal smoking status in pregnancy. We hypothesized
that, due to its strong association with smoking quantity,
there would be an association between the maternal risk
allele and lower offspring birth weight in women who
smoked during pregnancy, but no association with birth
weight in the non-smokers. Such an interaction would be inter-
preted within a Mendelian randomization context as providing
evidence of the causal nature of an association between mater-
nal smoking and offspring birth weight (18).
The 15q25 variant is strongly associated with lung cancer in
smokers. Several analyses have shown that the association
with self-reported number of cigarettes per day is insufficient
to explain the lung cancer association (12,19,20). These results
initially raised the possibility that the 15q25 variant might in-
crease vulnerability to the harmful effects of tobacco smoke in
those who are exposed, independently of smoking behaviour.
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If this were the case, we might expect to see an association
between fetal rs1051730 genotype and birth weight, which is
independent of maternal genotype, in the offspring of
mothers who smoked. However, a recent study showed a
stronger association with objectively measured cotinine
levels than with self-reported number of cigarettes per day.
This suggested that the locus works predominantly by influen-
cing tobacco exposure in smokers, and that although cigarettes
reported per day have the advantage of enabling the necessar-
ily large sample sizes for genetic association studies, they fail
to capture smoking exposure fully (21). Based on this, and
other recent evidence (22), we would not expect to observe
an association between fetal rs1051730 genotype and birth
weight that is independent of maternal genotype. We exam-
ined evidence of association between fetal rs1051730 geno-
type and birth weight in 25 090 offspring from 11 studies. In
a subset of 12 489 mother–offspring pairs from eight
studies, we were able to test the association between fetal
genotype and birth weight that was independent of maternal
genotype.
RESULTS
The basic characteristics of study participants are presented in
Table 1.
Association between maternal rs1051730 genotype and
offspring birth weight
In women who smoked during pregnancy, each additional
T-allele, which is associated with greater smoking quantity,
was associated with a 0.04 standard deviation (SD) (95% CI:
0.01–0.08 SD) lower birth weight (P ¼ 0.014). This equates,
approximately, to a reduction of 20 g (95% CI: 4–36 g) per
T-allele. However, in the never-smokers, we estimated only
a 0.01 SD change in birth weight per maternal T-allele (95%
CI: 20.01 to 0.03 SD) [or 5 g (95% CI: 24 to 14 g); P ¼
0.260; Table 2; Fig. 1A; see Supplementary Material,
Table S2 for individual study results]. There was little detect-
able heterogeneity within the non-smoking and smoking strata
[I2 ¼ 21.5% (95% CI: 0–68), P ¼ 0.220 for non-smokers;
I2 ¼ 0% (95% CI: 0–55), P ¼ 0.997 for pregnancy
smokers]. However, there was evidence of heterogeneity
between the strata (P ¼ 0.007), indicating an interaction
between genotype and smoking status in their association
with birth weight.
The effect size estimates observed for both smoking and
non-smoking pregnancies were similar (i) when adjusting for
fetal rs1051730 genotype in available samples, and (ii) in a
sensitivity analysis excluding the studies with less certain
smoking exposure data [BWHHS (The British Women’s
Heart and Health Survey), MIDSPAN and NCCGP (North
Cumbria Community Genetics Project); Table 2].
For 4279 women who smoked during pregnancy, data were
available on whether or not they continued to smoke after the
first trimester. There was evidence of heterogeneity between
the effect size estimates in the first trimester smokers and con-
tinued smokers (P ¼ 0.035; Fig. 1B). In women who reported
smoking only during the first trimester, the estimated change
in birth weight per T-allele was a 0.04 SD increase [95%
CI: 20.03 to 0.12 SD; (P ¼ 0.259); equivalent to an increase
of 21 g (95% CI: 215 to 57 g)] per T-allele. In contrast, we
observed an association between genotype and a 0.05 SD
lower birth weight per T-allele (95% CI: 0.01–0.10 SD;
P ¼ 0.028), in women who smoked beyond the first trimester.
This is equivalent to a reduction of 24 g (95% CI: 3–45 g) per
T-allele.
Association between fetal rs1051730 genotype and
offspring birth weight
In a meta-analysis of the 25 090 offspring with fetal rs1051730
genotype available, we observed no evidence of association
with birth weight in the offspring whose mothers did not
smoke in pregnancy [0.00 SD (95% CI: 20.01 to 0.02 SD;
P ¼ 0.665; equivalent to 0 g (95% CI: 25 to 9 g)]. There
was moderate heterogeneity in the non-smoking group [I2 ¼
43.8% (95% CI: 0–72), P ¼ 0.058]. In the offspring whose
mothers did smoke during pregnancy, the estimated change
in birth weight per T-allele was 20.03 SD [(95% CI:
20.06 to 0.01 SD; P ¼ 0.108; equivalent to 214 g (95%
CI: 229 to 5 g); Supplementary Material, Figure S1]. Low
heterogeneity was observed for smokers [I2 ¼ 0.0% (95%
CI: 0–60), P ¼ 0.618]. Weak evidence of heterogeneity was
observed between the two groups (P ¼ 0.105). On adjustment
for maternal rs1051730 genotype, the effect size estimates
were 0.01 SD (95% CI: 20.02 to 0.04 SD; P ¼ 0.634)
[equivalent to 5 g increase in birth weight (95% CI: 29 to
19 g)] and 20.02 SD (20.08 to 0.04 SD; P ¼ 0.538) [equiva-
lent to a 9 g reduction in birth weight (95% CI: 238 to 19 g)]
in the offspring of non-smoking and smoking mothers, re-
spectively. Low heterogeneity was observed for both groups
[non-smokers: I2 ¼ 0.0% (95% CI: 0–68), P ¼ 0.900;
smokers: I2 ¼ 12.0% (95% CI: 0–71), P ¼ 0.333]. No evi-
dence of heterogeneity was observed between the two
groups (P ¼ 0.444).
DISCUSSION
In a meta-analysis of 26 241 women from 14 studies, we have
found strong evidence of a gene × environment interaction
between maternal smoking behaviour and genotype of the
15q25 variant, rs1051730, in relation to offspring birth
weight (P ¼ 0.007). In women who smoked during pregnancy,
there was evidence that each additional copy of the T-allele,
which is associated with higher smoking quantity, was asso-
ciated with a 20 g (95% CI: 4–36 g) reduction in offspring
birth weight. In non-smoking mothers, the estimated change
in birth weight was 5 g (95% CI: 24 to 14 g) per T-allele. Al-
though the result is as expected, given prior knowledge of the
role of the SNP in smoking behaviour and the observational
link between smoking and low birth weight, the result pro-
vides an important proof-of-principle: when clearly defined,
genetic and behavioural risk factors can interact to influence
a phenotype.
Our results strengthen the evidence that maternal cigarette
smoking during pregnancy is causally associated with lower
offspring birth weight. Conventional epidemiological studies
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Table 1. Basic characteristics of study participants
Study Sample group Mothers, na (% of
male offspring)
Age in years,
mean (SD)
Mean birth weight of
offspring in grams
(SD)
Median gestational age at
delivery in weeks (IQR)
N available for fetal
genotype analysis
ALSPAC All pregnancies 6323 (50.8) 28.4 (4.7) 3474 (477) 40 (39–41) 6875
Non-smoking
pregnancies
4687 (50.2) 29.0 (4.5) 3516 (469) 40 (39–41) 5226
Smoking in the first
trimester only
313 (51.8) 26.9 (5.1) 3535 (507) 40 (39–41) 336
Smoking continued
after the first
trimester
1049 (53.2) 26.7 (5.0) 3308 (461) 40 (39–41) 1035
Total smoking
pregnancies
1636 (52.6) 26.6 (5.0) 3356 (480) 40 (39–41) 1649
BWHHS All pregnancies 2211 (48.3) NA 3297 (542) NA NA
Non-smoking
pregnancies
1702 (49.0) NA 3293 (543) NA NA
Smoking in the first
trimester only
NA NA NA NA NA
Smoking continued
after the first
trimester
NA NA NA NA NA
Total smoking
pregnancies
509 (46.0) NA 3312 (537) NA NA
DNBC-GOYA All pregnancies 1804 (52.0) 29.2 (4.2) 3643 (495) 40 (39–41) NA
Non-smoking
pregnancies
1338 (52.2) 29.4 (4.1) 3683 (491) 40 (39–41) NA
Smoking in the first
trimester only
154 (51.9) 28.0 (4.5) 3695 (504) 40 (39–41) NA
Smoking continued
after the first
trimester
312 (51.0) 28.6 (4.6) 3447 (459) 40 (39–41) NA
Total smoking
pregnancies
466 (51.6) 28.4 (4.6) 3434 (454) 40 (39–41) NA
DNBC-PTB All pregnancies 991 (52.6) 29.8 (4.0) 3701 (465) 40 (40–41) 991
Non-smoking
pregnancies
731 (53.4) 30.1 (3.8) 3760 (449) 40 (40–41) 731
Smoking in the first
trimester only
60 (53.3) 28.7 (4.0) 3634 (516) 41 (40–41) 60
Smoking continued
after the first
trimester
178 (50.6) 29.3 (4.6) 3516 (452) 40 (40–41) 178
Total smoking
pregnancies
260 (53.4) 29.1 (4.5) 3535 (470) 40 (40–41) 260
EFSOCH All pregnancies 808 (51.7) 30.5 (5.1) 3512 (474) 40 (39–41) 712
Non-smoking
pregnancies
650 (52.3) 31.2 (4.7) 3545 (467) 40 (39–41) 566
Smoking in the first
trimester only
48 (45.8) 28.4 (5.7) 3598 (378) 41 (39–41) 42
Smoking continued
after the first
trimester
91 (50.5) 27.6 (5.7) 3280 (509) 40 (39–41) 87
Total smoking
pregnancies
158 (49.4) 27.8 (5.7) 3375 (479) 40 (39–41) 146
Generation R All pregnancies 3384 (49.5) 31.2 (4.5) 3529 (498) 40 (39–41) 2258
Non-smoking
pregnancies
2512 (49.0) 31.6 (4.1) 3567 (495) 40 (39–41) 1731
Smoking in the first
trimester only
303 (49.2) 31.0 (4.3) 3539 (488) 40 (39–41) 196
Smoking continued
after the first
trimester
569 (51.5) 29.8 (5.6) 3353 (479) 40 (39–41) 331
Total smoking
pregnancies
872 (50.7) 30.2 (5.2) 3418 (490) 40 (39–41) 527
Continued
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Table 1. Continued
Study Sample group Mothers, na (% of
male offspring)
Age in years,
mean (SD)
Mean birth weight of
offspring in grams
(SD)
Median gestational age at
delivery in weeks (IQR)
N available for fetal
genotype analysis
HAPO All pregnancies 3661 (51.3) 30.5 (5.4) 3524 (463) 40 (39–41) 2872
Non-smoking
pregnancies
3113 (51.2) 30.8 (5.3) 3560 (453) 40 (39–41) 2480
Smoking in the first
trimester only
NA NA NA NA NA
Smoking continued
after the first
trimester
NA NA NA NA NA
Total smoking
pregnancies
548 (51.6) 28.3 (5.9) 3321 (466) 40 (39–41) 392
MIDSPAN All pregnancies 700 (49.5)b 27.3 (4.8) 3458 (485) 40 (40–40) NA
Non-smoking
pregnancies
408 (49.3)b 27.8 (4.7) 3533 (459) 40 (40–40) NA
Smoking in the first
trimester only
NA NA NA NA NA
Smoking continued
after the first
trimester
NA NA NA NA NA
Total smoking
pregnancies
292 (49.7)b 26.5 (4.8) 3341 (501) 40 (40–40) NA
MoBa All pregnancies 763 (46.0) 28.8 (3.4) 3682 (419) 40 (39–41) 521
Non-smoking
pregnancies
660 (47.1) 29.0 (3.3) 3689 (416) 40 (39–41) 482
Smoking in the first
trimester only
NA NA NA NA NA
Smoking continued
after the first
trimester
NA NA NA NA NA
Total smoking
pregnancies
103 (38.8) 27.5 (4.0) 3642 (415) 40 (39–41) 39
NCCGP All pregnancies 567 (46.7) 28.7 (5.7) 3445 (496) 40 (39–41) 544
Non-smoking
pregnancies
425 (44.7) 29.6 (5.1) 3493 (501) 40 (39–41) 406
Smoking in the first
trimester only
NA NA NA NA NA
Smoking continued
after the first
trimester
NA NA NA NA NA
Total smoking
pregnancies
142 (52.8) 25.9 (6.4) 3300 (451) 40 (39–40) 138
NFBC1966c All pregnancies 2068 (49.6) 26.3 (3.8) 3522 (469) 40 (38–42) 4721
Non-smoking
pregnancies
1748 (49.3) 26.4 (3.8) 3545 (464) 40 (38–42) 3873
Smoking in the first
trimester only
110 (49.1) 23.5 (3.2) 3499 (422) 40 (39–41) NA
Smoking continued
after the first
trimester
210 (51.9) 27.1 (3.4) 3347 (495) 40 (39–41) NA
Total smoking
pregnancies
320 (50.9) 25.8 (3.8) 3399 (476) 40 (39–41) 848
Raine All pregnancies 1206 (51.2) 28.9 (5.7) 3459 (472) 39 (38–40) 1266
Non-smoking
pregnancies
904 (53.3) 29.5 (5.6) 3516 (471) 39 (38–40) 942
Smoking in the first
trimester only
45 (48.9) 25.6 (5.8) 3438 (369) 39 (38–40) 47
Smoking continued
after the first
trimester
215 (46.0) 27.6 (5.8) 3248 (434) 39 (38–40) 231
Total smoking
pregnancies
302 (45.0) 27.1 (5.7) 3288 (431) 39 (38–40) 324
Continued
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are at risk of confounding by lifestyle or socioeconomic
factors. Genetic variants should not be related to the confound-
ing factors that distort associations in conventional observa-
tional epidemiological studies (23). We have shown
previously that the rs1051730 variant is not associated with
several confounding factors of smoking behaviour (e.g. age,
education level and occupation) (15). Hence, we can be confi-
dent that the association we have observed between maternal
rs1051370 genotype and offspring birth weight, together
with the null association in never-smokers, reflects a causal re-
lationship between smoking during pregnancy and birth
weight when considered within a Mendelian randomization
framework (18). These data add to the evidence from previous
epidemiological studies and clinical trials (6,9,24–30).
Each additional risk allele of rs1051730 is associated with
approximately one extra cigarette per day reported by
smokers (12,21). Our effect size estimates of a 20 g (95%
CI: 4–36 g) lower birth weight per allele in smokers and a
24 g (95% CI: 3–45 g) lower birth weight per allele in
women who smoked beyond the first trimester represent
unconfounded estimates of this exposure on birth weight.
These estimates are consistent with evidence from a prospect-
ive study of maternal smoking during pregnancy which
reported a 27 g lower birth weight per cigarette per day
smoked in the third trimester (31). As a consequence of the
relatively small effect sizes, genetic variation at the 15q25
locus would be expected to explain only a very small propor-
tion of the association between low birth weight and adverse
health outcomes in the offspring.
Subdivision of the pregnancy-smoker group showed evi-
dence that the association between maternal genotype and
birth weight may differ depending on whether women
smoked during the first trimester only [21 g (95% CI:
215 to 57 g) increase in birth weight per T-allele] or contin-
ued to smoke beyond the first trimester [24 g (95% CI: 3–
45 g) lower birth weight per T-allele]. Although power was
limited, particularly in the women who smoked only in the
first trimester, there was evidence of heterogeneity between
the strata (P ¼ 0.035). This suggests, in line with previous evi-
dence (31), that if women quit smoking during the first trimes-
ter of pregnancy, the adverse effects of smoking on birth
weight are reduced. This result should, however, be treated
with some caution. We stratified the data on whether or not
women gave up smoking, which may be influenced both by
rs1051730 genotype (15) and by smoking quantity, which
itself influences birth weight. Stratification on smoking cessa-
tion could therefore potentially induce distorted relationships
between genotype and birth weight. Women who continue
smoking are likely to be heavier smokers than those who do
not, and this might apply especially to the T-allele carriers.
Further studies are necessary to ascertain the extent of this
problem, for example, using cotinine levels as a more reliable
indicator of smoking quantity.
Studies of the association between the 15q25 variant and
lung cancer have reported a stronger association with disease
than can be accounted for by the quantity of cigarettes per
day (12,19,20). Possible explanations for this include the
likely scenario that the quantity of cigarettes per day fails to
Table 1. Continued
Study Sample group Mothers, na (% of
male offspring)
Age in years,
mean (SD)
Mean birth weight of
offspring in grams
(SD)
Median gestational age at
delivery in weeks (IQR)
N available for fetal
genotype analysis
1958BC_T1DGCc All pregnancies 836 (49.9) 25.8 (5.4) 3379 (469) 40 (40–41) 1985
Non-smoking
pregnancies
551 (50.3) 26.9 (5.5) 3438 (460) 41 (40–41) 1190
Smoking in the first
trimester only
82 (50.0) 24.4 (4.1) 3458 (421) 40 (40–42) 650
Smoking continued
after the first
trimester
203 (48.8) 23.3 (4.6) 3188 (461) 41 (40–41) 145
Total smoking
pregnancies
285 (49.1) 23.6 (4.5) 3266 (465) 41 (40–41) 795
1958BC_WTCCC2c All pregnancies 919 (49.6) 26.0 (5.3) 3328 (477) 40 (40–41) 2345
Non-smoking
pregnancies
582 (50.7) 27.1 (5.2) 3372 (483) 40 (40–41) 1431
Smoking in the first
trimester only
225 (50.2) 23.7 (4.8) 3189 (461) 40 (40–41) 746
Smoking continued
after the first
trimester
112 (42.9) 24.7 (4.7) 3380 (421) 40 (40–42) 168
Total smoking
pregnancies
337 (47.8) 24.0 (4.8) 3252 (456) 40 (40–41) 914
IQR, inter-quartile range; NA, not available.
aN includes mothers with genotype of rs1051730, smoking status and birth weight, sex and gestational age of offspring available.
bIn the MIDSPAN study, analysis allowed for multiple offspring per mother: n ¼ 1479 pregnancies (896 non-smoking; 583 smoking).
cThe fetal rs1051730 genotype analyses of the NFBC1966, 1958BC_T1DGC and 1958BC_WTCCC2 studies relate to births of the mothers themselves, in addition
to other participants in these birth cohorts (with maternal smoking data obtained from their own mothers). For all other studies, the fetal genotype analyses were
performed on the offspring of the women included in the analyses of maternal rs1051730 genotype.
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capture smoking exposure fully, but also have raised the pos-
sibility that the 15q25 variant might increase vulnerability to
the harmful effects of tobacco smoke independently of
smoking behaviour. To test whether the effects of maternal
smoking exposure could be modified by the fetal genotype
of rs1051730, we additionally examined evidence of associ-
ation between fetal rs1051730 genotype and birth weight in
25 090 offspring from 11 studies. Maternal and fetal genotypes
are correlated (r ≈ 0.5), so if there is no true association
between fetal genotype and birth weight, we would still
expect to observe an effect size of approximately half the mag-
nitude of the association between maternal genotype and birth
weight in offspring of smoking pregnancies. Our observed
effect size estimate of 214 g (95% CI: 229 to 5 g) is consist-
ent with this expectation. On adjustment for maternal geno-
type in 12 489 mother–offspring pairs, the estimate of the
association between fetal genotype and birth weight that is in-
dependent of maternal genotype was 29 g (95% CI: 238 to
19 g). Together our results suggest that any influence of the
rs1051730 variant on birth weight is mediated by maternal
smoking behaviour. This supports the hypothesis that the
CHRNA5–CHRNA3–CHRNB4 locus works wholly through
modulating smoking behaviour and not by an alternative
mechanism.
We acknowledge some limitations to our study. First, in
BWHHS, MIDSPAN and NCCGP, we made some assump-
tions regarding smoking status in pregnancy due to incomplete
data. This may have resulted in a misclassification of preg-
nancy smokers versus non-smokers. However, a sensitivity
analysis excluding these studies produced very similar effect
size estimates of the associations within each stratum.
Second, the individual studies in the meta-analysis used differ-
ent collection and classification methods for the smoking data.
We found little evidence of heterogeneity between studies
within each stratum. Third, smoking status was self-reported,
and previous studies using biochemical markers suggest that
women may not admit to smoking during pregnancy (32).
Any such misreporting is likely to result in an underestimate,
rather than an overestimate of the difference between smokers
and non-smokers. In addition, a recent meta-analysis, which
included the BWHHS and MIDSPAN studies, has shown
strong agreement between associations of the rs1051730
variant and both self-reported cigarettes per day and cotinine
levels (21). Fourth, our statistical evidence for association
with birth weight in the pregnancy smokers (P ¼ 0.014), and
for the genotype × smoking status interaction (P ¼ 0.007), is
modest in relation to levels now considered necessary for
robust genetic association studies (33). However, the evidence
for association between rs1051730 and smoking quantity is
extremely robust, giving high prior odds of association with
birth weight, and the strength of evidence we have observed
is as expected, given the available power and effect size esti-
mates.
In conclusion, the maternal rs1051730 variant is associated
with lower birth weight when mothers smoke during preg-
nancy, but not in non-smoking mothers. In mothers who
smoked beyond the first trimester of pregnancy, there was
an association between the variant and lower birth weight,
but not in mothers who smoked only in the first trimester, al-
though this observation requires further careful evaluation.T
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Our study strengthens the evidence that smoking during preg-
nancy is causally related to lower birth weight.
MATERIALS AND METHODS
Study participants
We analysed data on a total of 26 241 pregnant women and
25 090 offspring from 14 study samples. Participants were
included in our analyses if they were of European descent.
Only singleton births of gestational age ≥37 weeks were ana-
lysed. None of the contributing studies had data available on
cotinine levels measured during pregnancy, so we used self-
reported smoking status. All participants gave informed
consent and ethical approval was obtained from the relevant
local review committees.
The Avon Longitudinal Study of Parents and Children
This is a prospective study which recruited pregnant women
from Bristol, UK, with expected delivery dates between
Figure 1. Meta-analysis plots of the association between maternal rs1051730 genotype and offspring birth weight, stratified by maternal smoking status. (A)
Pregnancies of non-smoking versus smoking mothers. There was evidence of heterogeneity between the strata (P ¼ 0.007). In the smoking pregnancies, the
effect size equates to a 20 g (95% CI: 4–36 g) lower birth weight per T-allele. In the non-smoking pregnancies, there was no evidence of association [birth
weight difference per T-allele: 5 g (95% CI: 24 to 14 g)]. (B) Pregnancies of non-smoking mothers versus mothers who smoked only in the first trimester
versus mothers who continued to smoke after the first trimester. There was evidence of heterogeneity between the first trimester smoking and continued
smoking strata (P ¼ 0.035). There was no evidence of association in the first trimester smoking pregnancies [birth weight difference per T-allele: 21 g (95%
CI: 215 to 57 g)]. However, in pregnancies of continued smokers, there was a 24 g (95% CI: 3–45 g) lower birth weight per T-allele.
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April 1991 and December 1992 (34,35). Ethical approval was
obtained from the ALSPAC (Avon Longitudinal Study of
Parents and Children) Law and Ethics Committee in addition
to the local National Health Service (NHS) Research Ethics
Committee. Details of smoking behaviour, collected from
questionnaires administered in the 18th and 32nd gestational
weeks, have been described previously (15). Birth weight
and gestational age were obtained from obstetric records. In
the current analyses, we included 6323 women and 6875 chil-
dren with rs1051730 genotype, birth weight and smoking data
available.
The British Women’s Heart and Health Survey
The BWHHS study randomly selected and recruited 4286
women aged 60–79 years, from 23 British towns, between
1999 and 2001 (36). At baseline, the women were interviewed,
examined, completed questionnaires and had detailed reviews
of their medical records. Smoking history (never, former and
current, including details of age started and quit) was self-
reported at baseline, either at the research nurse interview or
in the mailed questionnaires (with very high levels of agree-
ment between both sources when data were available from
both). The study had no direct information about pregnancy
Figure 1. Continued
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smoking status. However, the women were born between 1920
and 1940 and predominantly gave birth to their offspring
between 1940 and 1970. This period was prior to public
health warnings about the adverse effects of smoking during
pregnancy. We therefore assumed that women who started
smoking before the age of 21 and who quit after the age of
45 continued to smoke during pregnancy. The birth weight,
sex and gestational age of the first-born child were collected
via questionnaires. Gestational age was recorded as ‘early’,
‘on-time’ or ‘late’ and therefore exclusion of women who
gave birth earlier than 37 weeks was not possible. A total of
2211 women were included in the analysis after the exclusion
of participants with non-European ethnicity or who had
missing rs1051730 genotype, smoking or birth weight data.
Fetal genotype was not available.
Danish National Birth Cohort—Genetics of Extreme Over-
weight in Young Adults and Preterm Birth Controls studies
The Danish National Birth Cohort (DNBC) is a collection of
data on 92 274 pregnant women recruited between 1996 and
2002, from their first antenatal visit to their general practition-
er. Women were interviewed twice during pregnancy (16 and
30 weeks gestation). Smoking data were collected during the
first pregnancy interview, where women were asked about
smoking during early pregnancy and about current smoking
status at the time of the interview. Birth weight and gestational
age were obtained from registry data, based on obstetric
records.
The DNBC contributed data from two substudies. A total of
1804 women from a randomly drawn sample of the DNBC
mothers were genotyped as part of the Genetics of Extreme
Overweight in Young Adults (GOYA) study (37,38) and
included in our meta-analysis. The Preterm Birth Controls
(PTB) substudy of the DNBC also contributed 991 women
to our meta-analysis, who had infants delivered at 39 or
40 weeks of gestation (39). Fetal genotype was available for
the DNBC-PTB study (n ¼ 991), but for not the
DNBC-GOYA study. A total of 19 women, who met our in-
clusion criteria, were recruited to both the DNBC-GOYA
and DNBC-PTB studies. These women were excluded from
the DNBC-GOYA sample to ensure that they were not
counted twice in the meta-analyses.
The Exeter Family Study of Childhood Health (EFSOCH)
This is a prospective study of children born between 2000 and
2004, and their parents, from a geographically defined region
of Exeter, UK (40). A questionnaire was administered during
the 28th gestational week, asking about lifetime, pre-
pregnancy, first trimester and current smoking quantity.
Birth weight was measured by trained study personnel, and
gestational age was collected from obstetric records. We
included 808 women and 712 offspring with rs1051730 geno-
type, birth weight and maternal smoking data available.
Generation R
The Generation R Study is a population-based prospective
cohort study from fetal life until young adulthood in a multi-
ethnic urban population in Rotterdam, the Netherlands (41).
Information about maternal smoking was obtained by self-
administered questionnaires in the first, second and third
trimesters. Smoking at enrolment was assessed in the first
questionnaire by asking each woman whether she smoked
during pregnancy (categories: no smoking, first trimester
only smoking, continued smoking). This questionnaire was
sent to all women, regardless of the gestational age at enrol-
ment. To assess smoking habits in the second and third trime-
sters, women were asked whether they smoked in the past
2 months (categories: no, yes) in the second and third ques-
tionnaires. Birth weight and gestational age data were obtained
from medical records and hospital registries. In the current
analysis, 3384 women of European descent with rs1051730
genotype, birth weight and maternal smoking data available
were included. Fetal genotype data were also available for
2258 offspring meeting our inclusion criteria.
Hyperglycemia and Adverse Pregnancy Outcome study
The Hyperglycemia and Adverse Pregnancy Outcome
(HAPO) study was designed to investigate the role of maternal
hyperglycaemia on pregnancy outcome (42). Birth weight
measurements by trained study personnel, and ascertainment
of gestational age data, have been described in detail previous-
ly (43). The study participants attended their local study centre
for a visit at 24–32 weeks of gestation. Prior to, or during, this
visit, they were asked how many cigarettes they had smoked,
on average, per day during this pregnancy. For the purposes of
the current study, the answers of the respondents were classi-
fied as non-smokers or smokers. The HAPO study contributed
3661 women and 2872 offspring of European descent to our
current analysis. These participants were recruited from nine
study centres: Bellflower, CA, USA (n ¼ 62); Chicago, IL,
USA (n ¼ 250); Providence, RI, USA (n ¼ 35); Cleveland,
OH, USA (n ¼ 204); Toronto, Canada (n ¼ 326); Belfast,
UK (n ¼ 754); Manchester, UK (n ¼ 1024); Brisbane, Austra-
lia (n ¼ 689); Newcastle, Australia (n ¼ 317).
MIDSPAN family study
There are four MIDSPAN population cohorts in Scotland (44).
The three original studies took place between 1964 and 1976.
In 1996, the next generation was studied, when 2338 (1298
female and 1040 male) offspring aged 30–59 years of
couples from the Renfrew/Paisley Study were recruited into
the Family Study. The birth weight and gestational age for
1825 births from 828 women in the Family Study that had
reported at least one pregnancy prior to screening were
recorded by questionnaires. Smoking during pregnancy was
derived from data detailing the age at which smoking com-
menced, smoking ceased and age at birth. It was assumed
that smokers who smoked while pregnant did not temporarily
reduce or stop smoking during pregnancy. Where this assump-
tion is wrong, non-exposed pregnancies will be miscategorized
as exposed, and the effect on birth weight underestimated. An-
ecdotal evidence suggests women became much more likely to
cut down or stop over the decades from the 50s to the 90s, so
miscategorization due to unreported pauses in smoking around
pregnancy will become more frequent in later decades and the
negative effect of smoking on birth weight will appear to
lessen over the decades. To test this, births were categorized
by year of birth into 50s–60s (number of mothers smoking
while pregnant ¼ 146 out of 295), 70s–80s (number of
mothers smoking while pregnant ¼ 267 out of 645) and 90s
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(number of mothers smoking while pregnant ¼ 170 out of
539), and tested for an interaction between this variable and
smoking while pregnant (P ¼ 0.69). There was no evidence
for a reduction over time in the effect of smoking on birth
weight, so no strong evidence of miscategorization of preg-
nancies as exposed. A sensitivity analysis, using a conserva-
tive version of smoking during pregnancy (excluding women
who started or stopped smoking within 2.5 years of giving
birth), gave very similar results. After removal of 210 births
(59 mothers) with missing or inconsistent data regarding preg-
nancies or maternal smoking behaviour, twin births and births
with gestational age below 37 weeks, and a further 136 births
(69 mothers) due to missing maternal rs1051730 genotype, the
current analyses included 700 mothers and 1479 births. Fetal
genotype was not available.
The Norwegian Mother and Child Cohort Study
The Norwegian Mother and Child Cohort Study (MoBa) study
is a nation-wide pregnancy cohort that from 1999 to 2008
included more than 107 000 pregnancies. It is maintained at
the Norwegian Institute of Public Health. Pregnant women
were invited to participate through a postal invitation after
they signed up for routine ultrasound examination in their
local hospital. The participation rate was 43% (45). The
women were asked to provide biological samples and to
answer questionnaires during pregnancy and after birth up to
the age of 7 for the child. The first questionnaire, answered
in gestational weeks 15–17, covered health, chemical and
physical factors in the environment, lifestyles and socio-
economic and demographic factors, and the second question-
naire was a food frequency questionnaire answered
prospectively in regard to spontaneous preterm delivery
outcome. The records of the participating women in the
Medical Birth Registry of Norway (MBRN) were included
in the data set (45). This study uses version 4 of the data
files made available for research in 2008. The study has
been approved by the Regional Committee for Ethics in
Medical Research and the Data Inspectorate in Norway. A
total of 763 women were included in our analyses, with geno-
type data available for 521 offspring.
North Cumbria Community Genetics Project
The NCCGP is a community-based DNA-banking project,
consisting of DNA and tissue samples from approximately
3000 mothers and approximately 7000 offspring born
between 1996 and 2003 (46). Maternal smoking status
during pregnancy was determined by a self-report question-
naire completed within the first 12 weeks of pregnancy. Spe-
cifically, pregnant mothers were asked whether they were
currently smoking and if they had smoked at all during the
pregnancy, responses from which were utilized to classify par-
ticipants as non-smokers or smokers. Reported details regard-
ing lifetime smoking habits were limited, hence it was not
always possible to distinguish ever-smokers from never-
smokers prior to this pregnancy. Birth weight and gestational
age were obtained from hospital records. A total of 567
women were included in our analyses, with rs1051730 geno-
type data available for 544 offspring.
Northern Finland 1966 Birth Cohort (NFBC1966)
This study includes individuals born in the two northernmost
provinces of Finland to mothers with expected dates of deliv-
ery in 1966 (47). The participants of the NFBC 1966 cohorts
were used in both the fetal and maternal analyses. A total of
2068 women included within the birth cohort, with
rs1051730 genotype, gave birth and were included in our ‘Ma-
ternal genotype’ meta-analysis. Maternal smoking, birth
weight and gestational age data were collected from birth
registry of their first-born offspring who met our inclusion cri-
teria. For the analyses of fetal rs1051730 genotype, we were
able to include 4721 participants from the birth cohort (includ-
ing the 2068 women) with medical record data on their own
birth weights and ‘smoking in pregnancy’ data collected
from their mothers via a questionnaire.
The Raine study
The Western Australian Pregnancy Cohort (Raine) study is a
prospective pregnancy cohort that recruited 2900 pregnant
women between May 1989 and November 1991. Self-reported
maternal smoking status was collected from questionnaires at
18 and 34 weeks of gestation. Birth weight was measured im-
mediately after birth by midwives, and gestational age was
ascertained based on the date of the last menstrual period
(48). The current analysis included 1206 women and 1266 off-
spring who met our inclusion criteria.
The 1958 British Birth Cohort (1958BC-T1DGC and
1958BC-WTCCC2)
The 1958BC is a national cohort of UK subjects born during
the same week in March 1958 (49). For the analysis of
smoking status and maternal genotype, information is from
the cohort members (genotype and smoking during pregnancy)
and their first born offspring (birth weight and gestational
age). Maternal smoking status prior to and during pregnancy
and information on birth weight and gestational age for the
first-born offspring were obtained by a structured question-
naire. For the analysis of smoking status and fetal genotype,
information is from cohort members (genotype, birth weight
and gestational age) and their mothers (smoking in preg-
nancy). ‘Smoking in pregnancy’ data came from maternal
report after the birth, and birth weight and gestational age of
the cohort members were obtained from their medical
records. Genetic information was obtained through two sub-
samples from case–control studies that had used the
1958BC as a source for population controls: 3000 samples
were randomly selected as part of the Wellcome Trust Case
Control Consortium [WTCCC2, (50)] and 2592 distinct
samples were selected as part of the Type 1 Diabetes Genetics
Consortium [T1DGC (51)]. In our meta-analyses of maternal
genotype data, we included 836 and 919 women from the
T1DGC and WTCCC2 subsamples, respectively. In our
meta-analyses of fetal genotype data, the respective totals
were 1985 and 2345 offspring.
Genotyping and quality control
The rs1051730 polymorphism was genotyped in all available
samples. The genotyping method and quality control summar-
ies are presented in Supplementary Material, Table S1.
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Statistical methods
Analyses in individual studies
Within each study, we stratified by maternal smoking status.
For our main analyses, women were classified as smokers or
non-smokers during pregnancy. For our second analyses, in
the eight studies with available information, pregnancy
smokers were further divided into those who smoked only in
the first trimester and those who continued to smoke after
the first trimester. We excluded multiple births, births before
37 weeks of gestation and individuals of non-European
descent from all analyses. Birth weight (BW) was standar-
dized to Z-scores within each included sample [(BW
value 2 mean BW)/SD of BW]. To test for an association
between birth weight and maternal rs1051730 genotype
within each stratum, we performed linear regression of birth
weight Z-score against genotype (coded as 0, 1 or 2
T-alleles; additive genetic model), with offspring sex and ges-
tational age as covariables. In the HAPO study, the analysis
was additionally adjusted for study centre. In the MIDSPAN
study, which included information on multiple offspring per
mother, the data are multilevel, with birth weights being clus-
tered within mothers, who are nested within families. The ana-
lysis model was fitted using the lme function in the nlme
package in R (www.r-project.org), with random intercepts
for families and mothers within families.
Fetal rs1051730 genotype was available for analysis in 11
studies (Table 1). The association between fetal genotype
and birth weight Z-score was analysed by linear regression
within each stratum, within each study, with the same covari-
ables and exclusions as used in the analyses of maternal geno-
type.
Maternal and fetal genotypes are correlated (r ≈ 0.5). To
examine the associations with birth weight of maternal and
fetal genotypes independently of one another, we used
mother–offspring pairs in eight studies (n ¼ 12 489;
ALSPAC, EFSOCH, DNBC-PTB, Generation R, HAPO,
MoBa, NCCGP, Raine). We checked for Mendelian errors,
and any pairs demonstrating inconsistencies were excluded
from our analysis. Within each of these studies, we performed
a linear regression analysis of birth weight Z-score against ma-
ternal genotype, fetal genotype, sex and gestational age in both
the pregnancy smoking and non-smoking strata.
Meta-analyses
We combined the regression coefficients and standard errors
from the individual study analyses by performing inverse vari-
ance meta-analyses with fixed effects in each of the smoking
or non-smoking strata (defined above). We additionally per-
formed a sensitivity analysis, excluding the three studies in
which assumptions were made about pregnancy smoking
exposures due to incomplete data (BWHHS, MIDSPAN and
NCCGP). All meta-analyses were performed using the
METAN module, developed for STATA (52), and a P-value
,0.05 was considered to represent evidence of association.
We estimated the percentage of total variation among study
estimates that is due to between-study heterogeneity using
the I2 statistic (53) and derived 95% CIs for this statistic
using the user-written Stata command, ‘heterogi’. Convention-
ally, I2 values of 25, 50 and 75% represent low, moderate and
high heterogeneity, respectively. Additionally, we used
Cochran’s Q-test to evaluate the statistical evidence for
between-study heterogeneity, both within and between the
strata defined by smoking status. The test of heterogeneity
between strata served as a test of interaction between genotype
and smoking status.
Estimation of approximate overall effect sizes in grams
To convert the overall results from birth weight Z-scores into
grams, we multiplied the effect size and 95% CI values by a
representative value of the SD of birth weight. We took the
median study SD of birth weight within each stratum as the
representative value (479 g for pregnancy smokers; 472 g for
non-smokers).
Power calculation
Our sample of 6230 women who smoked during pregnancy
and 20 011 pregnancy non-smokers gave us, respectively,
88% and .99% power to detect an effect on birth weight of
28 g (15) per maternal rs1051730 risk allele (frequency
38%) at P, 0.05 (two-sided, assuming a mean birth weight
of 3500 g and an SD of 480 g). The equivalent power esti-
mates in the sample of 6032 offspring with fetal genotype
available from smoking pregnancies and 19 058 offspring
from non-smoking pregnancies were 88% and .99%, respect-
ively.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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